ACC: Ultrasound Renal Denervation Cuts BP in Med-Resistant HTN
Reduction in daytime ambulatory systolic blood pressure at two months greater with ultrasound renal denervation versus sham procedure
MONDAY, May 24, 2021 (HealthDay News) -- Ultrasound renal denervation reduces blood pressure compared with a sham procedure among patients with hypertension resistant to a standardized triple combination pill, according to a study published online May 16 in The Lancet to coincide with the annual meeting of the American College of Cardiology, held virtually from May 15 to 17.
Michel Azizi, M.D., from the Université de Paris, and colleagues conducted a randomized single-blind, sham-controlled trial involving patients aged 18 to 75 years with office blood pressure of at least 140/90 mm Hg despite three or more antihypertensive medications, including a diuretic. Patients were switched to a once-daily, fixed-dose, single pill combination of a calcium channel blocker, angiotensin receptor blocker, and thiazide diuretic. Those with daytime ambulatory blood pressure of at least 135/85 mm Hg after four weeks of therapy were randomly assigned to either ultrasound renal denervation or a sham procedure (69 and 67 patients, respectively).
The researchers found that compared with the sham procedure, there was a greater reduction in daytime ambulatory systolic blood pressure at two months with renal denervation (−8.0 versus −3.0 mm Hg, respectively; median between-group difference, −4.5 mm Hg). Among patients with complete ambulatory blood pressure data, the median between-group difference was −5.8 mm Hg. There were no differences observed between the groups in safety outcomes.
"Follow-up of the present population for three years as well as additional studies will be important to evaluate the durability, continued safety, and long-term clinical impact of ultrasound renal denervation in patients with various forms of hypertension," the authors write.
Several authors disclosed financial ties to pharmaceutical and medical device companies, including ReCor Medical, which funded the trial.